{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:33:36Z","timestamp":1791686016207,"version":"4.3.4"},"reference-count":21,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"32","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2025,11,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Older patients with ALL receiving conventional chemotherapy have poor survival due to toxic death and relapse. We hypothesized that a chemotherapy-free, targeted regimen using the anti-CD22 antibody-calicheamicin conjugate inotuzumab ozogamicin followed by the bispecific anti-CD19\/CD3 T-cell engager blinatumomab would reduce toxic death and yield high rates of prolonged remission and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Eligible patients were age 60 years and older with untreated, Philadelphia chromosome (Ph)\u2013negative, CD22-positive, B-cell ALL. Patients received up to two cycles of inotuzumab ozogamicin followed by four or five cycles of blinatumomab with intrathecal methotrexate CNS prophylaxis. The primary end point was 1-year event-free survival (EFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The 33 eligible patients had a median age of 71 years (range, 60-84) and a median CD22 expression of 92% (range, 21%-100%). Eight (24%) had previous chemotherapy or radiation for other cancers, six for multiple myeloma. The composite complete remission rate was 85% after two cycles of inotuzumab ozogamicin and 97% by the end of two cycles of blinatumomab. At a median follow-up of 30 months, the 1-year EFS and overall survival were 75% (95% CI, 61 to 92) and 85% (95% CI, 73 to 98), respectively. EFS was shorter with lower CD22 expression or detectable measurable residual disease at any time point.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Inotuzumab ozogamicin then blinatumomab without maintenance chemotherapy in older patients with untreated, Ph-negative, CD22-positive, B-cell ALL yields a high remission rate and excellent EFS. Given the lack of standard, safe, and effective therapies in this population, the regimen should be considered a standard treatment option.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-00307","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:59:26Z","timestamp":1759262366000},"page":"3526-3535","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":13,"title":["Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03739814","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5414-9228","authenticated-orcid":true,"given":"Matthew J.","family":"Wieduwilt","sequence":"first","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3242-9664","authenticated-orcid":true,"given":"Jun","family":"Yin","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oudom","family":"Kour","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Teske","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8349-9200","authenticated-orcid":true,"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-3647","authenticated-orcid":true,"given":"Carolin","family":"Escherich","sequence":"additional","affiliation":[{"name":"St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-9659","authenticated-orcid":true,"given":"Jun","family":"Yang","sequence":"additional","affiliation":[{"name":"St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Li","sequence":"additional","affiliation":[{"name":"St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Byrd","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Doucette","sequence":"additional","affiliation":[{"name":"Georgetown University Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mangan","sequence":"additional","affiliation":[{"name":"University of California San Diego Medical Center, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Hall","sequence":"additional","affiliation":[{"name":"Helen F. Graham Cancer Center and Research Institute, Newark, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8971-2199","authenticated-orcid":true,"given":"Alice S.","family":"Mims","sequence":"additional","affiliation":[{"name":"The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Jamieson","sequence":"additional","affiliation":[{"name":"University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira N.","family":"Dinner","sequence":"additional","affiliation":[{"name":"Alliance Protocol Operations Office, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali W.","family":"Bseiso","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Giordano","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caner","family":"Saygin","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-0996","authenticated-orcid":true,"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":true,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-2633","authenticated-orcid":true,"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Partners Cancer Care, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-379016"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26156"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00490"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00073-X"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7006"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00546"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01766"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27617"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025"},{"key":"e_1_3_9_15_2","first-page":"1556","article-title":"A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111","volume":"92","author":"Larson RA","year":"1998","unstructured":"Larson RA, Dodge RK, Linker CA, et al: A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 92:1556-1564, 1998","journal-title":"Blood"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11219"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-045351"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2016272"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008216"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01075"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00272"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004813"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-00307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T22:59:35Z","timestamp":1762383575000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-00307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":21,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2025,11,10]]}},"alternative-id":["10.1200\/JCO-25-00307"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-00307","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"2025-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}